Novacyt (NCYT)

149.30
-0.70(-0.47%)
  • Volume:
    103,468
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    143.80 - 149.30

NCYT Overview

Prev. Close
150
Day's Range
143.8-149.3
Revenue
-
Open
146.25
52 wk Range
131.17-497.3
EPS
-
Volume
103,468
Market Cap
103.51M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
318,290
P/E Ratio
1.18
Beta
-
1-Year Change
-58.77%
Shares Outstanding
70,614,619
Next Earnings Date
31 May 2022
What is your sentiment on Novacyt?
or
Market is currently closed. Voting is open during market hours.

Novacyt News

Novacyt Company Profile

Novacyt Company Profile

Employees
283
Market
France

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralStrong SellSell
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • i need help, how do I begin buying share
    1
    • Open an account with a Stockbroker.This is easily done online .Read reviews of best online brokers How much are their fees, commission.Do they offer an advisory service?Join a free bulletin board such as advfn or lse and ask politely for advice on brokers.That's all.
      1
    • If you have money to burn it than you will find the way.
      1
  • Takeover?
    1
    • It does’nt matter what other countries policies are about covid-omicron, as long as it is active un USA it means it is it is problem for rest if the world, as everyting USA dictates not England or other any other country.
      0
      • Volume of testing will fall as Omicron fades and travel testing is reduced.Will Novacyt fall in tandem; some experts saying Strong Buy?
        3
        • Great call jonny, as always
          3
          • haha lets see by June, i made the call on 16th Dec, it closed 367. If im wrong, im wrong & admit it. N hopefully learn something
            0
        • head and shoulders. looks like it will fall to 150p
          6
          • maybe when COVID goes away, until then 750 easy.
            1
        • Why is this stock bring hit so negatively. The demand for PCR tests is rocketing view the variant and international travel regulations etc.This producer of such tests should be benefitting hugely.What are we missing here after their earlier sharp falls ?
          1
          • Market always look forward rather than rear view mirror
            0
          • Looking Forward the demand for covid tests will acceletate tremendously in view of Omicron concern globally.
            0
          • Yes, that's already priced in. The trick of investing/trading cyclical stock is to buy when pe is highest and sell when pe is lowest
            0
        • Kaching
          0
          • Elliot wave anaysis suggests there's an opportunity for this stock to be bottoming here
            2
            • I missed that. What does that mean?
              2
          • Dramatic climb today? does anyone know why?
            1